What is the 13F Pro Quality Score for HBIO?

13F Pro ranks HARVARD BIOSCIENCE INC (HBIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HBIO's current score at https://13fpro.ai/research/HBIO (free sign-up required for the full ranking).

Where does 13F Pro source HBIO data?

All HARVARD BIOSCIENCE INC fundamentals and ownership data come directly from SEC EDGAR. HARVARD BIOSCIENCE INC files with the SEC under CIK 1123494. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HBIO in?

HARVARD BIOSCIENCE INC (HBIO) is classified in the Technology sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/technology.

How often is HBIO research updated on 13F Pro?

HBIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HARVARD BIOSCIENCE INC(HBIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Technology →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1123494 HBIO stock profile & AI dashboard →

13F Pro Quality Score

20.8/100

Rank #2,669 of 2,879 stocks

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

10.7/100

Profitability

15.5/100

Balance Sheet

11.6/100

Earnings Quality

30.0/100

Free Cash Flow

53.4/100

Institutional Flow

0.6/100

Revenue Scale

15.5/100

Dilution Risk

40.1/100

HBIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for HARVARD BIOSCIENCE INC (HBIO), a Technology sector company. 13F Pro's AI-powered ranking engine scores HBIO at 20.8/100 on a 32-signal composite quality model, placing it at rank #2,669 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (0.6) and revenue growth (10.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 40.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), HARVARD BIOSCIENCE INC reports quarterly revenue of $20.8M, net income of $-3.4M, free cash flow of $-1.1M. Top institutional holders of HBIO by reported 13-F value include WEBER CAPITAL MANAGEMENT /ADV, VANGUARD CAPITAL MANAGEMENT, CORSAIR CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. HBIO trades on the Nasdaq exchange and files with the SEC under CIK 1123494. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HARVARD BIOSCIENCE INC directly from SEC EDGAR. HARVARD BIOSCIENCE INC's 13F Pro composite quality score has ranged between 14 and 33 since 2021, currently 20.8 — a declining long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about HARVARD BIOSCIENCE INC

Quirks, history, and lore behind HBIO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. life sciences company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the range of $100–150 million — not a giant, but a specialist serving research labs and biotech firms worldwide.
3
The History
Traces its roots back to the 1990s, built through a series of acquisitions that assembled a portfolio of precision instruments under one roof.
4
The Secret
Its bread and butter is making equipment that keeps living cells and tissues alive outside the body — think bioreactors, pumps, and surgical tools for research.
5
The Lore
Its brands include Denville Scientific and Biochrom, supplying the unglamorous but essential plumbing of modern biology — the stuff every lab needs but nobody tweets about.
6
The Giveaway
The name sounds like an Ivy League side project, but this Holliston, MA company makes apparatus for life science research and trades under a ticker that nods squarely at Harvard… Bioscience.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$20.8M

Net Income

Q1 2026

$-3.4M

Free Cash Flow

Q1 2026

$-1.1M

D/E Ratio

Q1 2026

3.60

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-1.0% YoY

$112.3MFY 2023

FY19 $116.2MFY20 $102.1MFY22 $113.3MFY23 $112.3M

Net Income

+64.1% YoY

$-3.4MFY 2023

FY19 $-4.7MFY20 $-7.8MFY22 $-9.5MFY23 $-3.4M

Operating Income

+127.3% YoY

$1.9MFY 2023

FY19 $377.0KFY20 $221.0KFY22 $-6.9MFY23 $1.9M

EPS (Diluted)

+65.2% YoY

$-0.08FY 2023

FY19 $-0.12FY20 —FY22 $-0.23FY23 $-0.08

Total Assets

-5.5% YoY

$137.4MFY 2023

FY19 $164.9MFY20 $156.3MFY22 $145.4MFY23 $137.4M

Total Debt

-15.4% YoY

$43.1MFY 2023

FY19 $57.0MFY20 $50.0MFY22 $50.9MFY23 $43.1M

Op. Cash Flow

+1117.7% YoY

$14.0MFY 2023

FY19 $8.0MFY20 $9.3MFY22 $1.2MFY23 $14.0M

Metric	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2016
Revenue	$112.3M -1.0%	$113.3M +11.0%	$102.1M -12.1%	$116.2M -3.8%	$120.8M +15.5%	$104.5M
Net Income	$-3.4M +64.1%	$-9.5M -21.8%	$-7.8M -66.6%	$-4.7M -60.4%	$-2.9M +32.2%	$-4.3M
Operating Income	$1.9M +127.3%	$-6.9M -3237.1%	$221.0K -41.4%	$377.0K -61.7%	$984.0K +132.8%	$-3.0M
EPS (Diluted)	$-0.08 +65.2%	$-0.23	—	$-0.12 -50.0%	$-0.08 +38.5%	$-0.13
Total Assets	$137.4M -5.5%	$145.4M -7.0%	$156.3M -5.2%	$164.9M -2.2%	$168.6M +56.5%	$107.8M
Total Debt	$43.1M -15.4%	$50.9M +1.8%	$50.0M -12.3%	$57.0M -9.8%	$63.2M +356.3%	$13.8M
Operating Cash Flow	$14.0M +1117.7%	$1.2M -87.7%	$9.3M +16.0%	$8.0M +179.0%	$2.9M -46.4%	$5.4M

AI Insight: HBIO Financial Trends

HBIO faces severe financial deterioration: revenue flat-to-declining at ~$21M, net income volatile with two large losses, and equity collapsed 85% from Q2 2024 to Q1 2026.

• Revenue declined from $23M (Q2 2024) to $21M (Q1 2026), down 9% over 8 quarters with no sustained growth.

• Equity eroded from $67M to $10M; Q1 2025 loss of $50M triggered a 76% equity drop in single quarter.

• Operating cash flow near-zero or negative in recent quarters (Q1 2026: -$1M); profitability swings wide.

⚠ Debt-to-equity ratio spiked from 0.6x (Q2 2024) to 3.6x (Q1 2026) despite debt reduction; balance sheet highly leveraged.

⚠ Q4 2025 reported $44M net loss; source and sustainability of this charge unclear from table alone.

AI Insight: HBIO Ratio Trends

HBIO swung from near-breakeven in Q4 2025 to sharp losses across all profitability metrics in Q1 2026, with leverage spiking to 3.60x D/E.

• Operating margin collapsed to -5.7% in Q1 2026 from +7.2% in Q4 2025, a 12.9pp deterioration in a single quarter.

• ROIC swung from +13.8% in Q4 2025 to -10.2% in Q1 2026, erasing prior quarter gains.

• Debt-to-equity ratio rose to 3.60x at TTM (Mar 2026), matching the peak from mid-2024 amid persistent unprofitability.

⚠ Net profit margin shows extreme volatility: -16.5% in Q1 2026 after +195.2% anomaly in Q3 2025, signaling potential one-off items masking operational health.

⚠ Return on equity plunged to -136.3% in Q1 2026; TTM ROE at -97.4% suggests sustained capital destruction.

Get alerted when HBIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HARVARD BIOSCIENCE INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HBIO

WEBER CAPITAL MANAGEMENT LLC /ADV
$1.6M320,037 sh
VANGUARD CAPITAL MANAGEMENT LLC
$795.3K163,313 sh
CORSAIR CAPITAL MANAGEMENT, L.P.
$607.8K124,810 sh
Meros Investment Management, LP
$577.2K118,522 sh
NANO CAP NEW MILLENNIUM GROWTH FUND L P
$572.2K117,500 sh
TWO SIGMA INVESTMENTS, LP
$555.8K114,117 sh
RENAISSANCE TECHNOLOGIES LLC
$493.9K101,427 sh
BlackRock, Inc.
$303.0K62,226 sh
GEODE CAPITAL MANAGEMENT, LLC
$289.9K59,511 sh
MILLENNIUM MANAGEMENT LLC
$225.6K46,332 sh

Fund	Value	Shares
WEBER CAPITAL MANAGEMENT LLC /ADV	$1.6M	320,037
VANGUARD CAPITAL MANAGEMENT LLC	$795.3K	163,313
CORSAIR CAPITAL MANAGEMENT, L.P.	$607.8K	124,810
Meros Investment Management, LP	$577.2K	118,522
NANO CAP NEW MILLENNIUM GROWTH FUND L P	$572.2K	117,500
TWO SIGMA INVESTMENTS, LP	$555.8K	114,117
RENAISSANCE TECHNOLOGIES LLC	$493.9K	101,427
BlackRock, Inc.	$303.0K	62,226
GEODE CAPITAL MANAGEMENT, LLC	$289.9K	59,511
MILLENNIUM MANAGEMENT LLC	$225.6K	46,332

More Technology Companies

View all Technology →

AGILENT TECHNOLOGIES, INC.

AAOI

APPLIED OPTOELECTRONICS, INC.

AAPL

Apple Inc.

ABNB

Airbnb, Inc.

ACCL

Acco Group Holdings Ltd

ACCS

ACCESS Newswire Inc.

ACFN

ACORN ENERGY, INC.

ACIW

ACI WORLDWIDE, INC.

Put HBIO on your watchlist

Track score changes the day HARVARD BIOSCIENCE INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HBIO a good stock to buy?

13F Pro's AI-powered analysis of HARVARD BIOSCIENCE INC (HBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HBIO are available on the HBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HBIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HARVARD BIOSCIENCE INC's investment landscape.